We report the case of a 63-year-old woman with metastatic breast cancer, without pre-existing diabetes mellitus, who developed marked hyperglycemia after commencement of a novel PIK3CA inhibitor and review treatment options for PI3K inhibitor-associated hyperglycemia. Here, PIK3CA is linked to breast cancer.